GlassScriptPhysician profile
Ruston L Stoltz
NPI 1023011418
$4,876.20
in general payments reported to CMS, 2019-2025
44 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $354 · 2021: $910 · 2022: $548 · 2023: $901 · 2024: $826 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,737.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,457.61 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $501.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $332.28 | 2020-2025 | Shingrix, Arexvy, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $330.66 | 2021-2023 | |
| Pfizer INC. | $270.22 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $212.62 | 2023-2025 | Rexulti |
| Allergan, INC. | $169.66 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $163.03 | 2019-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Lilly USA, LLC | $120.45 | 2020-2025 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.78 | 2024-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.65 | 2022-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $100.30 | 2019-2024 | Airsupra |
| Abbott Laboratories | $87.24 | 2019-2020 | |
| Lundbeck LLC | $70.69 | 2023-2024 | Vyepti |
| Astellas Pharma US INC | $67.58 | 2019-2024 | Veozah |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruston Stoltz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.